Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo

Contrast Media and Molecular Imaging

Volumn 10, Issue 3, 2015, Pages 225-236

  Shanehsazzadeh, Saeed ^a   Gruettner, Cordula ^b   Lahooti, Afsaneh ^c   Mahmoudi, Morteza ^d   Allen, Barry J ^e   Ghavami, Mahdi ^f   Daha, Fariba Johari ^a   Oghabian, Mohammad Ali ^c,g  

^a NUCLEAR SCIENCE AND TECHNOLOGY RESEARCH INSTITUTE   (Iran)

^b MICROMOD PARTIKELTECHNOLOGIE GMBH   (Germany)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e UNIVERSITY OF WESTERN SYDNEY   (Australia)

^f PASTEUR INSTITUTE OF IRAN   (Iran)

^g TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Biodistribution; Breast cancer; C595 antibody; Nanoparticles; Protein corona; USPIO

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C595 ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE TC 99M; MUCIN 1; NANOPARTICLE; TECHNETIUM 99M; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; CONTRAST MEDIUM; FERRIC ION; FERRIC OXIDE; MAGNETITE NANOPARTICLE; MUC-1 MONOCLONAL ANTIBODY; TECHNETIUM; TUMOR ANTIGEN; TUMOR MARKER;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER CELL; FEMALE; HYDRODYNAMICS; IMAGE ANALYSIS; IMAGE QUALITY; IMMUNOREACTIVITY; IN VITRO STUDY; ISOTOPE LABELING; MAGNETOMETER; MICROSCOPE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURFACE PROPERTY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BREAST NEOPLASMS; CHEMISTRY; DISEASE MODEL; HUMAN; IMMUNOLOGY; LIVER; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PROCEDURES; SPLEEN; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL LINE, TUMOR; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; FEMALE; FERRIC COMPOUNDS; HUMANS; LIVER; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MUCIN-1; SPLEEN; TECHNETIUM;

EID: 84930907853     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1627     Document Type: Article

References (76)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63(1): 11-30.
2. Cope DG. Breast cancer: reviewing the past to give direction for the future. Oncol Nurs Forum 2013; 40(5): 425-428.
3. Jahanbakhsh R, Atyabi F, Shanehsazzadeh S, Sobhani Z, Adeli M, Dinarvand R. Modified Gadonanotubes as a promising novel MRI contrasting agent. DARU 2013; 21(6): 53. doi: 10.1186/2008-2231-21-53
4. Oghabian MA, Farahbakhsh NM. Potential use of nanoparticle based contrast agents in MRI: a molecular imaging perspective. J Biomed Nanotechnol 2010; 6(3): 203-213.
5. Shanehsazzadeh S, Oghabian MA, Daha FJ, Amanlou M, Allen BJ. Biodistribution of ultra small superparamagnetic iron oxide nanoparticles in BALB mice. J Radioanal Nucl Chem 2013; 295(2): 1517-1523.
6. Amanlou M, Siadat SD, Ebrahimi SES, Alavi A, Aghasadeghi MR, Ardestani MS, Shanehsaz S, Ghorbani M, Mehravi B, Alavidjeh MS, Jabbari-Arabzadeh A, Abbasi M. Gd3+-DTPA-DG: novel nanosized dual anticancer and molecular imaging agent. Int J Nanomed 2011; 6: 747-763.
7. Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, Muller RN. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev 2008; 108(6): 2064-2110.
8. Wunderbaldinger P, Josephson L, Weissleder R. Crosslinked iron oxides (CLIO): a new platform for the development of targeted MR contrast agents. Acad Radiol 2002; 9: S304-S306.
9. Shahbazi-Gahrouei D, Abdolahi M, Zarkesh-Esfahani SH, Laurent S, Sermeus C, Gruettner C. Functionalized magnetic nanoparticles for the detection and quantitative analysis of cell surface antigen. Biomed Res Int 2013; 2013: 9.
10. Boutry S, Laurent S, Elst LV, Muller RN. Specific E-selectin targeting with a superparamagnetic MRI contrast agent. Contrast Media Mol Img 2006; 1(1): 15-22.
11. Radermacher KA, Beghein N, Boutry S, Laurent S, Elst LV, Muller RN, Jordan BF, Gallez B. In vivo detection of inflammation using pegylated iron oxide particles targeted at E-selectin: a multimodal approach using MR imaging and EPR spectroscopy. Invest Radiol 2009; 44(7): 398-404.
12. Oghabian MA, Gharehaghaji N, Masoudi A, Shanehsazzadeh S, Ahmadi R, Majidi RF, Hosseini HRM. Effect of coating materials on lymph nodes detection using magnetite nanoparticles. Adv Sci Eng Med 2013; 5(1): 37-45.
13. Mahmoudi M, Hosseinkhani H, Hosseinkhani M, Boutry S, Simchi A, Journeay WS, Subramani K, Laurent S. Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine. Chem Rev 2010; 111(2): 253-280.
14. Shanehsazzadeh S, Oghabian M, Allen B, Amanlou M, Daha FJ. Evaluating the effect of USPIO nanoparticles for 21days post magnetic cell labeling. In World Congress on Medical Physics and Biomedical Engineering, 26-31 May 2012, Beijing. Springer: Berlin, 2013; 2204-2207.
15. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005; 19(3): 311-330.
16. Jones D. Cancer nanotechnology: small, but heading for the big time. Nat Rev Drug Discov 2007; 6(3): 174-175.
17. Weissleder R Molecular imaging in cancer. Science 2006; 312(5777): 1168-1171.
18. Croce MV, Isla-Larrain MT, Capafons A, Price MR, Segal-Eiras A. Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women. Breast Cancer Res Treat 2001; 69(1): 1-11.
19. Baldus SE, Wienand JR, Werner JP, Landsberg S, Drebber U, Hanisch FG, Dienes HP. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope. Int J Oncol 2005; 27(5): 1289-1297.
20. Denda-Nagai K, Irimura T. MUC1 in carcinoma-host interactions. Glycoconjug J 2000; 17(7-9): 649-658.
21. Price MR, Pugh JA, Hudecz F, Griffiths W, Jacobs E, Symonds IM, Clarke AJ, Chan WC, Baldwin RW. C595 - a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas. Br J Cancer 1990; 61(5): 681-686.
22. Moore A, Medarova Z, Potthast A, Dai G. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res 2004; 64(5): 1821-1827.
23. Tassa C, Shaw SY, Weissleder R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc Chem Res 2011; 44(10): 842-852.
24. Abdolahi M, Shahbazi-Gahrouei D, Laurent S, Sermeus C, Firozian F, Allen BJ, Boutry S, Muller RN. Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer. Contrast Media Mol Img 2013; 8(2): 175-184.
25. Pala K, Serwotka A, Jeleń F, Jakimowicz P, Otlewski J. Tumor-specific hyperthermia with aptamer-tagged superparamagnetic nanoparticles. Int J Nanomed 2014; 9: 67.
26. Shanehsazzadeh S, Oghabian MA, Lahooti A, Allen BJ. Development of ultra small super paramagnetic iron oxide nanoparticles labeled with Gallium 67 as a dual modality probe. J Labelled Compd Radiat 2013; 56: S236-S236.
27. Lahooti A, Shanehsazzadeh S, Jalilian AR, Tavakoli MB. Assessment of effective absorbed dose of (111)In-DTPA-buserelin in human on the basis of biodistribution rat data. Radiat Prot Dosim 2013; 154(1): 1-8.
28. Shanehsazzadeh S, Jalilian AR, Sadeghi HR, Allahverdi M. Determination of human absorbed dose of 67GA-DTPA-ACTH based on distribution data in rats. Radiat Prot Dosim 2009; 134(2): 79-86.
29. Jalilian AR, Sardari D, Kia L, Rowshanfarzad P, Garousi J, Akhlaghi M, Shanehsazzadeh S, Mirzaii M. Preparation, quality control and biodistribution studies of two [111In]-rituximab immunoconjugates. Sci Pharm 2008; 76(2): 151-170.
30. Jalilian A, Shanehsazzadeh S, Akhlaghi M, Kamali-Dehghan M, Moradkhani S. Development of [111In]-DTPA-buserelin for GnRH receptor studies. Radiochim Acta 2010; 98(2): 113-119.
31. Jalilian A, Shanehsazzadeh S, Akhlaghi M, Garousi J, Rajabifar S, Tavakoli M. Preparation and biodistribution of [67Ga]-DTPA-gonadorelin in normal rats. J Radioanal Nucl Chem 2008; 278(1): 123-129.
32. Mahanta S, Fessler SP, Park J, Bamdad C. A minimal fragment of MUC1 mediates growth of cancer cells. PLoS One 2008; 3(4): e2054.
33. Mahmoudi M, Shokrgozar MA, Sardari S, Moghadam MK, Vali H, Laurent S, Stroeve P. Irreversible changes in protein conformation due to interaction with superparamagnetic iron oxide nanoparticles. Nanoscale 2011; 3(3): 1127-1138.
34. Wang H, Wang J, Deng X, Sun H, Shi Z, Gu Z, Liu Y, Zhao Y. Biodistribution of carbon single-wall carbon nanotubes in mice. J Nanosci Nanotechnol 2004; 4(8): 1019-1024.
35. Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Kruger A, Gansbacher B, Plank C. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 2002; 9(2): 102-109.
36. Li Y, Pei Y, Zhang X, Gu Z, Zhou Z, Yuan W, Zhou J, Zhu J, Gao X. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release 2001; 71(2): 203-211.
37. DeNardo SJ, DeNardo GL, Natarajan A, Miers LA, Foreman AR, Gruettner C, Adamson GN, Ivkov R. Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF - induced thermoablative therapy for human breast cancer in mice. J Nucl Med 2007; 48(3): 437-444.
38. Rimkus G, Bremer-Streck S, Gruttner C, Kaiser WA, Hilger I. Can we accurately quantify nanoparticle associated proteins when constructing high-affinity MRI molecular imaging probes? Contrast Media Mol Imag 2011; 6(3): 119-125.
39. Hughes OD, Bishop MC, Perkins AC, Frier M, Price MR, Denton G, Smith A, Rutherford R, Schubiger PA. Preclinical evaluation of copper-67 labelled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer. Eur J Nucl Med 1997; 24(4): 439-443.
40. Omid H, Oghabian MA, Ahmadi R, Shahbazi N, Hosseini HRM, Shanehsazzadeh S, Zangeneh RN. Synthesizing and staining manganese oxide nanoparticles for cytotoxicity and cellular uptake investigation. Biochim Biophys Acta - Gen Subjects 2014; 1840(1): 428-433.
41. Biological Council. Guidelines on the use of living animals in scientific investigations, 1987.
42. Vande Velde G, Raman Rangarajan J, Vreys R, Guglielmetti C, Dresselaers T, Verhoye M, Van der Linden A, Debyser Z, Baekelandt V, Maes F. Quantitative evaluation of MRI-based tracking of ferritin-labeled endogenous neural stem cell progeny in rodent brain. Neuroimage 2012; 62(1): 367-380.
43. Lahooti A, Shanehsazzadeh S, Oghabian MA, Allen BJ. Assessment of human effective absorbed dose of Tc-99m-USPIO based on biodistribution rat data. J Labelled Compd Radiat 2013; 56: S258-S258.
44. Mahmoudi M, Shokrgozar MA, Behzadi S. Slight temperature changes affect protein affinity and cellular uptake/toxicity of nanoparticles. Nanoscale 2013; 5(8): 3240-3244.
45. Salouti M, Rajabi H, Babaei MH, Rasaee MJ. Breast tumor targeting with (99m)Tc-HYNIC-PR81 complex as a new biologic radiopharmaceutical. Nucl Med Biol 2008; 35(7): 763-768.
46. Mohammadnejad J, Rasaee MJ, Babaei MH, Paknejad M, Hasan ZM, Salouti M, Gandomkar M, Sadri K. Radioimmunotherapy of MCF7 breast cancer cell line with 131I-PR81 monoclonal antibody against MUC1: comparison of direct and indirect radioiodination methods. Hum Antibodies 2010; 19(1): 15-25.
47. Robin MB. The color and electronic configurations of Prussian blue. Inorg Chem 1962; 1(2): 337-342.
48. von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, Verstraeten AA, van Kamp GJ, Kok A, van Uffelen K, Snijdewint FG, Paul MA, Meijer S, Hilgers J. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumour Biol 1998; 19(3): 186-195.
49. Mitchell S, Abel P, Madaan S, Jeffs J, Chaudhary K, Stamp G, Lalani el N. Androgen-dependent regulation of human MUC1 mucin expression. Neoplasia 2002; 4(1): 9-18.
50. Giess CS, Frost EP, Birdwell RL. Difficulties and errors in diagnosis of breast neoplasms. Semin Ultrasound CT 2012; 33(4): 288-299.
51. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008; 148(9): 671-679.
52. Shanehsazzadeh S, Lahooti A, Sadeghi HR, Jalilian AR. Estimation of human effective absorbed dose of 67Ga-cDTPA-gonadorelin based on biodistribution rat data. Nucl Med Commun 2011; 32(1): 37-43.
53. Mahmoudi M, Simchi A, Milani AS, Stroeve P. Cell toxicity of superparamagnetic iron oxide nanoparticles. J Colloid Interface Sci 2009; 336(2): 510-518.
54. Mahmoudi M, Simchi A, Imani M, Häfeli UO. Superparamagnetic iron oxide nanoparticles with rigid cross-linked polyethylene glycol fumarate coating for application in imaging and drug delivery. J Phys Chem C 2009; 113(19): 8124-8131.
55. Mahmoudi M, Lynch I, Ejtehadi MR, Monopoli MP, Bombelli FB, Laurent S. Protein-nanoparticle interactions: opportunities and challenges. Chem Rev 2011; 111(9): 5610-5637.
56. Walczyk D, Bombelli FB, Monopoli MP, Lynch I, Dawson KA. What the cell 'sees' in bionanoscience. J Am Chem Soc 2010; 132(16): 5761-5768.
57. Monopoli MP, Åberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol 2012; 7(12): 779-786.
58. Dawson KA. Leave the policing to others. Nat Nanotechnol 2013; 8(2): 73.
59. Mahon E, Salvati A, Baldelli Bombelli F, Lynch I, Dawson KA. Designing the nanoparticle-biomolecule interface for 'targeting and therapeutic delivery'. J Control Release 2012; 161(2): 164-174.
60. Mitchell S, Abel P, Madaan S, Jeffs J, Chaudhary K, Stamp G, Lalani E-N. Androgen-dependent regulation of human MUC1 mucin expression. Neoplasia 2002; 4(1): 9.
61. Joshi MD, Ahmad R, Yin L, Raina D, Rajabi H, Bubley G, Kharbanda S, Kufe D. MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol Cancer Ther 2009; 8(11): 3056-3065.
62. Walsh M, Luckie S, Cummings M, Antalis T, McGuckin M. Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and in vitro. Breast Cancer Res Tr 1999; 58(3): 253-264.
63. Kondo S, Yoshizaki T, Wakisaka N, Horikawa T, Murono S, Jang KL, Joab I, Furukawa M, Pagano JS. MUC1 induced by Epstein-Barr virus latent membrane protein 1 causes dissociation of the cell-matrix interaction and cellular invasiveness via STAT signaling. J Virol 2007; 81(4): 1554-1562.
64. Taylor-Papadimitriou J, Burchell J, Miles D, Dalziel M. MUC1 and cancer. Biochim Biophys Acta - Molecular Basis of Disease 1999; 1455(2): 301-313.
65. Truant S, Bruyneel E, Gouyer V, De Wever O, Pruvot FR, Mareel M, Huet G. Requirement of both mucins and proteoglycans in cell-cell dissociation and invasiveness of colon carcinoma HT-29 cells. Int J Cancer 2003; 104(6): 683-694.
66. Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF, Ellis IO. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Modern Pathol 2005; 18(10): 1295-1304.
67. Qu CF, Songl YJ, Rizvi SM, Li Y, Smith R, Perkins AC, Morgenstern A, Brechbiel M, Allen BJ. In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A′′-C595. Cancer Biol Ther 2005; 4(8): 848-853.
68. Simms MS, Murray A, Denton G, Scholfield DP, Price MR, Perkins AC, Bishop MC. Production and characterisation of a C595 antibody-99mTc conjugate for immunoscintigraphy of bladder cancer. Urol Res 2001; 29(1): 13-19.
69. Wang J, Abbas Rizvi SM, Madigan MC, Cozzi PJ, Power CA, Qu CF, Morgenstern A, Apostolidis C, Russell PJ, Allen BJ, Li Y. Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates. Prostate 2006; 66(16): 1753-1767.
70. Medarova Z, Pham W, Kim Y, Dai G, Moore A. In vivo imaging of tumor response to therapy using a dual-modality imaging strategy. Int J Cancer 2006; 118(11): 2796-2802.
71. Medarova Z, Rashkovetsky L, Pantazopoulos P, Moore A. Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging. Cancer Res 2009; 69(3): 1182-1189.
72. Leung K. Ultrasmall superparamagnetic iron oxide nanoparticles conjugated with Ile-Pro-Leu-Pro-Phe-Tyr-Asn. 2004.
73. McLachlan SJ, Morris MR, Lucas MA, Fisco RA, Eakins MN, Fowler DR, Scheetz RB, Olukotun AY. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imag 1994; 4(3): 301-307.
74. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990; 175(2): 489-493.
75. Salvati A, Pitek AS, Monopoli MP, Prapainop K, Bombelli FB, Hristov DR, Kelly PM, Åberg C, Mahon E, Dawson KA. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 2013; 8(2): 137-143.
76. Mirshafiee V, Mahmoudi M, Lou K, Cheng J, Kraft ML. Protein corona significantly reduces active targeting yield. Chem Commun 2013; 49(21): 2557-2559.